Business
CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting
Findings from ALAMO Study Show AlloSure Lung is Associated with Prognosis of Chronic Lung Allograft Dysfunction and Restrictive Allograft Syndrome AlloSure
About this update from Caredx, Inc.
[{"type":"text","content":"\nFindings from ALAMO Study Show AlloSure Lung is Associated with Prognosis of Chronic Lung Allograft Dysfunction and Restrictive Allograft Syndrome\n\nAlloSure Lung Surveillance Monitoring Identifies the Onset of Acute Cellular Rejection and Treatment Response\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators, presented new scientific evidence on the use of AlloSure® Lung in clinical practice at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting & Scientific Sessions, held from April 27-30 in Boston, Massachusetts.\n\nAlloSure Lung and AlloHome™ were featured in 8 abstracts including 2 oral presentations and key findings were:\n\n\nSurveillance monitoring using AlloSure Lung effectively identified rising dd-cfDNA levels signaling onset of acute cellular rejection and decline in levels after treatment for rejection (Abstract 1627).\n\n\nAlloSure Lung was used to monitor safety and graft function of Tacrolimus (TAC) inhalation powder as a replacement to oral TAC in lung transplant patients with renal insufficiency (Abstract 143, oral session).\n\n\nAlloSure Lung was used to investigate the impact of TAC drug levels on the outcomes of DSA-positive lung transplant recipients over a one-year follow-up (Abstract 403, mini oral).\n\n\nAlloHome remote patient monitoring system in lung transplant enables real-time treatment adjustments and improved triage, easing workload on transplant center staff (Abstract 1204).\n\n\n“We are very pleased with the new data presented at ISHLT indicating that surveillance monitoring using AlloSure effectively detected rejection and could be used to monitor patient treatment responses,” said Robert Woodward, CareDx Chief Scientific Officer.\n\nAdditionally, during a CareDx sponsored symposium, an interim analysis of the ALAMO (AlloSure Lung Assessment and Metagenomics Outcomes) prospective, multi-center study showed that AlloSure Lung may be prognostic of Chronic Allograft Lung Dysfunction (CLAD), a leading cause of death after lung transplantation. Elevated lev...